The stage is set, and we’re ready to welcome you to #TCT2026 tomorrow! We are ready to what promises to be an exciting few days of groundbreaking science, innovation, and education. #TCT2026 #Cardiology #Innovation #CRF

I want to thank SCAI for trusting Kate, Arasi and me with this book. Hope the interventional community will find it useful. I want to specially thank Amanda Pettyjohn, who kept everyone on task and for her critical edits and reviews. Thanks to the chapter authors and reviewers.

Get ready to experience #TCT2026 like never before! 🌴 Meet our social media ambassadors and get exclusive, behind-the-scenes access to the latest breakthroughs in #interventionalcardiology. 🚀 ow.ly/5grH5102s6S #CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMd @djc795 @ColletCarlos @georgedangas @jgranadacrf @mbmcentegart @Drroxmehran @sahilparikhmd @PopmaJeffrey @triciarawh @mirvatalasnag @TCTConference @TCTMD @m1chaella_alex @CathWhisperer @caldera_99 @SinaDaneshMD @CAESmedmd @Julio_Farjat @GolzarianH @JyotiJain_MD @Shikha_Cardio @DrBilal_khan @KrutarthKPandya @Shoaib9702 @IoannisSkalidis @Sticchi_Alex @ricosuruagy @ladyheart_md @AnaClaraVi75147 @anast_apost @padideh_daneii @MAnisHaider @Rushil_Vasudev

RT @SrihariNaiduMD: Direct link: assets.bmctoday.net/citoday/… @Babar_Basir @KadoshBernard @SandeepNathanMD @seanvandiepen @thiele_holger @Navin…

県立西宮総合医療センターの新型アンギオ（血管撮影）はSFの世界。 集患戦略として最新機材はもっと全面に出したほうがいいな。

Tomorrow’s Cathlab toys 👉👉👉 tctconference.com/medtech-in… Let’s go 🌞 🌊 🏄

Good breakdown of the DK-crush approach here, 2 DES cases like this show what's achievable. More on my blog: dralo.net

RT @PeterHotez: My comments on the triumph of Arab science and their contribution to preserving Aristotle, Ptolemy, Euclid, Pythagoras, Arc…

New 2026 SCAI SHOCK ⚡️🫀💥 Classification Expert Consensus Update: Coming Very Very Soon at #AHA26 👍… @scai

A healthy 40-year old man was found to have a PFO on an otherwise normal echocardiogram (performed for palpitations . He has done research and wants it closed. Do you do it or refer for closure?

BETTER LATE THAN NEVER !

This year, TCT is stopping in San Diego (and I’ll have to take three flights to get there), and the late-breaking lineup is quite interesting. Here are my favourites, both journalistically and from an interventional cardiology perspective: 1/ P4, a trial of CCTA-guided vs IVUS-guided PCI. We published the design paper in EuroIntervention. Check it out: eurointervention.pcronline.c… 2/ TRANSFORM II, or DCB strategy vs DES, Act III. With REC-CAGEFREE I coming out negative and SELUTION DeNovo being so-so, we really needed a tiebreaker. And here it is. 3/ HD-PCI, a randomized trial of higher vs lower-dose heparin for PCI. I like trials that answer practical, “in or out” questions. I also have to discuss this one right after the presentation, so I’m studying it carefully. 4/ PROGRESS: TAVR or clinical surveillance for moderate aortic stenosis. I still haven’t quite figured out the ambition and magnitude of these TAVR trials in moderate AS. The first one, TAVR UNLOAD, didn’t leave much of a mark. We don’t know when EXPAND TAVR II will be presented, but I suspect it’ll be soon. And then there’s PROGRESS, the largest of them all in terms of patient numbers. By the way, ClinicalTrials.gov says follow-up will end in 2037. As we say back home, campa cavallo. 5/ SIMPLAAFY, antithrombotic monotherapy after left atrial appendage occlusion. I like this trial if only for its name, and I can’t wait to hear how people pronounce it. More importantly, it could give DAPT a serious shove out the door, since it seems to be the main burden holding back LAAO at the moment. 6/ PIONEER IV, angiography-derived FFR vs usual care for lesion selection and optimization in all-comers PCI. Another QFR trial occupying an intermediate position on the physiology spectrum between FAVOR III Europe and FAVOR III China. 7/ VERONICA, where researchers are trying to demonstrate the usefulness of platelet-function testing to identify patients with excessive platelet inhibition (usually, it’s the opposite) and see whether a de-escalation strategy could reduce the combined risk of ischemic and bleeding events.

Emboliner will be a game changer for PMA of left sided masses.

AngioVAC for left-sided intracardiac masses shows good effectiveness. Careful case selection, timely workup, and optimal embolic protection strategy are necessary. @PedroMDMSc @ShimamuraMD @DrMarvinEng @AhmadJabri8 @g_giustinoMD @vonBardelebenRS @engelpedro @Tiberio_Frisoli

Meta-analyses of intravascular imaging guidance of PCI show markedly improved outcomes, but only if you use this tool properly — pre-, intra- and post-PCI and with appropriate targets. How do you do it? Our new state-of-the-art review in EHJ takes you through it step by step.

Can someone explain to me why a professional football player was hospitalized for a suspected pulmonary embolus then was told not to sleep for about 36 hours ?

I pray with all my heart that the turmoil & violent demonstrations across Europe come to a peaceful halt as nobody wins , nobody benefits , nothing gets better , only worse !

Ellie Cohanim is advising Israel to criminalize the journalists who filmed terrorist Jewish settlers beating and stabbing Washington Post photographer Heidi Levine today @EllieCohanim currently serves as a top advisor to US ambassador to the UN Mike Waltz

George Orwell wrote about this

Heidi Levine in the hospital recounts the settler attack this morning